Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and...
Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 26, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage...